Treatment of Mucormycosis with Liposomal Amphotericin B, Posaconazole and Deferasirox: A Case Report
Abstract
Keywords
References
- 1. Zeka AN, Taşbakan M, Pullukçu H, et al. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013;47:708-716.
- 2. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634-653.
- 3. Aslan M, Öz Y, Akay MO, Akşit F. Evaluation of febrile neutropenia in hematologic malignancy patients. Mediterr J Infect Microb Antimicrob 2014; 3:20.
- 4. Özden M, Denk A, Demirdağ K, Elkıran T. Investigation of Febrile Neutropenic Cases and Risk Factors. Mediterr J Infect Microb Antimicrob 2014;2:3.
- 5. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis 2013. Clin Microbiol Infec 2014; 20 Suppl. 3:5-26.
- 6. Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007;117: 2649-2657.
- 7. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012;67:715-722.
- 8. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-378.
Details
Primary Language
Turkish
Subjects
Health Care Administration
Journal Section
Case Report
Authors
Uğur Önal
This is me
Publication Date
March 1, 2016
Submission Date
July 16, 2017
Acceptance Date
August 6, 2015
Published in Issue
Year 2016 Volume: 6 Number: 1